The JAK1/2 inhibitor (i), ruxolitinib, is currently employed in a phase II clinical trial study of Ph-like ALL patients bearing CRLF2 alterations (ClinicalTrials.gov Identifier: NCT02723994). The gene discussed is JAK1; the disease is acute lymphoblastic leukemia.